Free Trial
NASDAQ:PSTV

Plus Therapeutics (PSTV) Stock Price, News & Analysis

Plus Therapeutics logo
$0.46 -0.01 (-1.47%)
As of 10:37 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Plus Therapeutics Stock (NASDAQ:PSTV)

Key Stats

Today's Range
$0.46
$0.47
50-Day Range
$0.30
$0.80
52-Week Range
$0.16
$2.31
Volume
866,066 shs
Average Volume
18.32 million shs
Market Capitalization
$45.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.88
Consensus Rating
Buy

Company Overview

Plus Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

PSTV MarketRank™: 

Plus Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 398th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Plus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    Plus Therapeutics has a consensus price target of $7.88, representing about 1,575.9% upside from its current price of $0.47.

  • Amount of Analyst Coverage

    Plus Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Plus Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Plus Therapeutics are expected to grow in the coming year, from ($2.30) to ($1.60) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Plus Therapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Plus Therapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Plus Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    4.73% of the float of Plus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Plus Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Plus Therapeutics has recently increased by 49.36%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Plus Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Plus Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.73% of the float of Plus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Plus Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Plus Therapeutics has recently increased by 49.36%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Plus Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Plus Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 52 people have searched for PSTV on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
  • MarketBeat Follows

    15 people have added Plus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 7% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Plus Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $53,900.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 0.79% of the stock of Plus Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 3.28% of the stock of Plus Therapeutics is held by institutions.

  • Read more about Plus Therapeutics' insider trading history.
Receive PSTV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Plus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PSTV Stock News Headlines

NVDA: The cracks are beginning to show
The media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. Its hardware is in such high demand that in just one data center, there's enough of it to stretch around the Earth eight timestc pixel
D Boral Capital Upgrades Plus Therapeutics (NASDAQ:PSTV) to Strong-Buy
See More Headlines

PSTV Stock Analysis - Frequently Asked Questions

Plus Therapeutics' stock was trading at $1.15 at the beginning of the year. Since then, PSTV shares have decreased by 59.1% and is now trading at $0.4699.

Plus Therapeutics, Inc. (NASDAQ:PSTV) announced its quarterly earnings data on Thursday, August, 14th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.09) by $0.08. The firm earned $1.39 million during the quarter, compared to the consensus estimate of $1.08 million.

Plus Therapeutics shares reverse split on Monday, May 1st 2023.The 1-15 reverse split was announced on Monday, May 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Plus Therapeutics' top institutional shareholders include Jane Street Group LLC (0.19%). Insiders that own company stock include Robert P Lenk, Howard Clowes, Greg Petersen, Marc H Hedrick and Andrew John Hugh Macintyr Sims.
View institutional ownership trends
.

Shares of PSTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Plus Therapeutics investors own include Meta Platforms (META), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), NVIDIA (NVDA), Arista Networks (ANET), Broadcom (AVGO) and Adobe (ADBE).

Company Calendar

Last Earnings
8/14/2025
Today
9/12/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:PSTV
CIK
1095981
Employees
20
Year Founded
1996

Price Target and Rating

High Price Target
$20.50
Low Price Target
$3.00
Potential Upside/Downside
+1,575.9%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.98 million
Net Margins
-357.85%
Pretax Margin
-357.85%
Return on Equity
N/A
Return on Assets
-117.72%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.26
Quick Ratio
1.26

Sales & Book Value

Annual Sales
$5.82 million
Price / Sales
8.01
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.52) per share
Price / Book
-0.31

Miscellaneous

Outstanding Shares
99,260,000
Free Float
98,481,000
Market Cap
$46.64 million
Optionable
Not Optionable
Beta
0.66

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:PSTV) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners